WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & MediaAbout Us
Antibody Generation
WuXi Biologics offers the full spectrum of biological drug discovery services for the generation, selection, characterization and production of high potency, novel antibody therapeutics. We offer seven, integrated antibody discovery platforms for screening and lead identification of monoclonal, bispecific and multispecific abs or other biotherapeutic approaches such as antibody-drug conjugates (ADCs), antibody fragments (e.g., Fabs, scFVs) and Fc-fusion proteins. Based on your R&D goals, we advise and collaborate with you to tailor a program that best suits your technical and budgetary requirements. Each platform you utilize takes advantage of our core competencies:
- World-class research expertise
- State-of-the-art facilities
- Well-established project management systems
- Efficient workflows
- Demonstrated success in generating antibodies against a multitude of targets and identifying candidate antibodies in all disease areas
In addition, we offer novel antibody generation and engineering technology platforms for bispecific (WuXiBody®) and multispecific (SDarBody™) antibodies and antibody-drug conjugates (WuXiDAR4™).
WuXi Biologics offers multiple antibody engineering and generation platforms for the discovery of antibody-based therapeutics
WuXi Biologics provides antibody generation through traditional hybridoma approaches using our WuXiHybrid™ advanced hybridoma-monoclonal antibody technology platform. We also offer multiple approaches for generating fully human antibody using transgenic animals from either Ligand’s OmniAb® or Alloy Therapeutics’ ATX-Gx™ platforms. . WuXi Biologics has successfully delivered 200+ therapeutic antibody discovery projects via our hybridoma platform. We have extensive experience with GPCR (G Protein-Coupled Receptor) & other difficult targets.
Process and Timeline:
Key Features:
- Transgenic mice/rats for fully human antibody generation
- Multiple immunization strategies (DNA, peptide, protein, cell or combinations thereof) to generate the best-fit to the targets
- Proprietary immunization protocols to increase immune responses
- High fusion efficiency through electrofusion
- Semi-solid method for subcloning
- High throughput protein-based and cell-based screening platforms. Five high-throughput flow cytometers and seven Biacore instruments to support screening and affinity ranking.
- Functional screen using hybridoma supernatants to increase chances of isolating functional leads.
WuXi Biologics offers high-quality phage display library construction and customized library selection and screening services via our WuXiLiAb® human naïve phage display library and other antibody immune libraries.
WuXi Biologics has constructed human naïve libraries from 50+ donors with more than 1011 transformants representing nearly all human antibody V-gene repertoire:
- Naïve library panning/screening: 2-3 months.
- Immune library construction and screening: 3-4 months
Process and Timeline:
Key Features:
- In-house ready to use human naïve or synthetic libraries
- Immune (custom) libraries: human, mouse, rat, llama, alpaca, common light chain
- Liquid-phase, solid-phase and cell-based panning
-
Epitope guided and Avi-tag capture selections enable isolation of functionally active antibodies
WuXi Biologics offers high-quality alpaca/llama immune library construction and customized library selection and screening services. WuXi Biologics has constructed alpaca naïve libraries from 50+ alpaca donors with more than 1011 transformants:
- Naïve library panning/screening: 2-3 months.
- Immune library construction and screening: 3-4 months
Process and Timeline:
Key Features:
- Liquid-phase, solid-phase and cell-based panning
- In-house ready to use alpaca naïve libraries
-
Proprietary primer sets to achieve increased coverage of alpaca/llama VHH gene repertoire